PT101042A - Sistema de vectores de expressao miogenicos - Google Patents

Sistema de vectores de expressao miogenicos

Info

Publication number
PT101042A
PT101042A PT101042A PT10104292A PT101042A PT 101042 A PT101042 A PT 101042A PT 101042 A PT101042 A PT 101042A PT 10104292 A PT10104292 A PT 10104292A PT 101042 A PT101042 A PT 101042A
Authority
PT
Portugal
Prior art keywords
miogenic
expression vector
vector systems
systems
expression
Prior art date
Application number
PT101042A
Other languages
English (en)
Other versions
PT101042B (pt
Inventor
Robert J Schwartz
Franco J Demayo
Bert W O'malley
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of PT101042A publication Critical patent/PT101042A/pt
Publication of PT101042B publication Critical patent/PT101042B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C07K14/4708—Duchenne dystrophy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/90—Vector systems having a special element relevant for transcription from vertebrates avian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Eye Examination Apparatus (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT101042A 1991-11-06 1992-11-06 Sistema de vectores de expressao miogenicos PT101042B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/789,919 US5298422A (en) 1991-11-06 1991-11-06 Myogenic vector systems

Publications (2)

Publication Number Publication Date
PT101042A true PT101042A (pt) 1994-02-28
PT101042B PT101042B (pt) 1999-11-30

Family

ID=25149108

Family Applications (1)

Application Number Title Priority Date Filing Date
PT101042A PT101042B (pt) 1991-11-06 1992-11-06 Sistema de vectores de expressao miogenicos

Country Status (7)

Country Link
US (2) US5298422A (pt)
EP (1) EP0635060A4 (pt)
JP (1) JPH07500967A (pt)
AU (1) AU660751B2 (pt)
CA (1) CA2122617A1 (pt)
PT (1) PT101042B (pt)
WO (1) WO1993009236A1 (pt)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925564A (en) * 1991-11-06 1999-07-20 Baylor College Of Medicine Expression vector systems and method of use
US6348327B1 (en) * 1991-12-06 2002-02-19 Genentech, Inc. Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
EP0745121B1 (en) * 1992-05-14 2007-06-20 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US6416998B1 (en) 1992-09-02 2002-07-09 Baylor College Of Medicine Plasmid encoding a modified steroid hormone
EP0646178A1 (en) * 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US6264915B1 (en) 1992-09-13 2001-07-24 The President And Fellows Of Harvard College Process for detecting potential carcinogens
GB9310441D0 (en) * 1993-05-20 1993-07-07 Royal Free Hosp School Med Gene therapy
FR2711670B1 (fr) * 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US5962427A (en) 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
US20020193338A1 (en) * 1994-02-18 2002-12-19 Goldstein Steven A. In vivo gene transfer methods for wound healing
US6025183A (en) * 1994-02-28 2000-02-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Transgenic animal assay system for anti-cholinesterase substances
IL112820A0 (en) * 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression
US6995008B1 (en) 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
WO1995034640A1 (en) * 1994-06-13 1995-12-21 Henry Ford Health System A novel neuronal-neonatal gene: neuronatin
US5444047A (en) * 1994-06-16 1995-08-22 Dipasquale; Gene Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I
GB9419048D0 (en) * 1994-09-20 1994-11-09 Watt Diana J Treatment of muscular disorders
WO1996010401A1 (en) * 1994-10-04 1996-04-11 Emory University Methods for regulation of insulin-like growth factor i receptor
US20030152909A1 (en) * 1994-11-16 2003-08-14 Mitrani Eduardo N. In vitro micro-organs, and uses related thereto
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
US5728807A (en) * 1995-05-16 1998-03-17 Ramot-University Authority For Applied Research And Industrial Development, Ltd. Mutated proteins associated with ataxia-telangiectasia
US5777093A (en) * 1995-05-16 1998-07-07 Ramot-University Authority For Applied Research & Industrial Development Ltd. cDNAs associated with ataxia-telangiectasia
US5858661A (en) 1995-05-16 1999-01-12 Ramot-University Authority For Applied Research And Industrial Development Ataxia-telangiectasia gene and its genomic organization
FR2736642B1 (fr) * 1995-07-10 1997-09-12 Pasteur Institut Immunovecteurs, notamment anticorps et fragments d'anticorps utilisables pour le transport intracellulaire et intranucleaire de principes biologiquement actifs notamment d'haptenes, de proteines et d'acides nucleiques
KR19990044317A (ko) * 1995-09-01 1999-06-25 라미 핀클러 ; 하나넬 크바탄스키 아밀포스파타제2Ｃ - ＰＰ 2Ｃα-발현의 조작 및 검출
EP0871729A1 (en) 1995-09-15 1998-10-21 Baylor College Of Medicine Steroid receptor coactivator compositions and methods of use
US5795872A (en) * 1995-09-19 1998-08-18 Pharmadigm, Inc. DNA construct for immunization
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
US7119174B2 (en) 1995-12-18 2006-10-10 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
GB9605124D0 (en) 1996-03-11 1996-05-08 Royal Free Hosp School Med Method of treating muscular disorders
US6140309A (en) * 1996-03-12 2000-10-31 University Of South Florida Vasoactive effects and free radical generation by β-amyloid peptides
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
US7074589B1 (en) 1996-06-17 2006-07-11 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Nucleic acids encoding BDP-1
AU727028B2 (en) * 1996-06-25 2000-11-30 Ludwig Institute For Cancer Research Brain glycogen phosphorylase cancer antigen
CA2259123C (en) 1996-07-01 2003-10-21 Lorus Therapeutics Inc. Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth
JP2000516090A (ja) * 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
US5898094A (en) * 1996-10-21 1999-04-27 University Of South Florida Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
EP0935657B1 (en) * 1996-10-29 2007-08-29 Baylor College Of Medicine Modified steroid hormone receptors
US6387700B1 (en) * 1996-11-04 2002-05-14 The Reagents Of The University Of Michigan Cationic peptides, Cys-Trp-(LYS)n, for gene delivery
US6335010B1 (en) 1996-11-08 2002-01-01 University Of California At San Diego Gene therapy in coronary angioplasty and bypass
AU719629B2 (en) 1996-11-08 2000-05-11 Oklahoma Medical Research Foundation Endothelium specific expression regulated by EPCR control elements
US6004791A (en) 1996-11-13 1999-12-21 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Protein tyrosine phosphatase PTP20 and related products and methods
US6541615B1 (en) 1996-11-15 2003-04-01 Max-Planck-Gellschaft Zur Foderung Der Wissenschaften E.V. SIRP proteins and uses thereof
US6136581A (en) * 1996-11-22 2000-10-24 Sugen, Inc. Kinase genes and uses
DE69731660T2 (de) * 1996-12-02 2005-12-22 Valentis Inc., Burlingame Insulinähnlicher wachstumfaktor i (igf-i) expressionssystem und methode zur verwendung
US6797513B2 (en) 1996-12-19 2004-09-28 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Nucleic acid encoding CLK2 protein kinases
CA2279577A1 (en) * 1997-02-04 1998-08-06 Valentis, Inc. Treatment for urinary incontinence using gene therapy techniques
US6489451B1 (en) 1997-04-10 2002-12-03 Hefei-Siu-Fung Ustc Pharmaceutical Co., Ltd. Antithrombosis enzyme from the snake venom of agkistrodon acutus
US6818440B2 (en) 1997-04-28 2004-11-16 Sugen, Inc. Diagnosis and treatment of alk-7 related disorders
US6228641B1 (en) 1997-05-20 2001-05-08 Sugen, Inc. Diagnosis and treatment of PTP04 related disorders
US7115710B2 (en) 1997-06-11 2006-10-03 Sugen, Inc. Diagnosis and treatment of PTP related disorders
US6342593B1 (en) 1997-06-11 2002-01-29 Sugen, Inc. Diagnosis and treatment of ALP related disorders
US20050096288A1 (en) * 1997-06-13 2005-05-05 Aragene, Inc. Lipoproteins as nucleic acid vectors
US6635623B1 (en) 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
US6388063B1 (en) 1997-06-18 2002-05-14 Sugen, Inc. Diagnosis and treatment of SAD related disorders
AU8569698A (en) 1997-07-11 1999-02-08 Brandeis University Method of inducing apoptosis by reducing the level of thiamin
GB9715064D0 (en) * 1997-07-17 1997-09-24 Ppl Therapeutics Scotland Ltd Protein expression
AU8589998A (en) * 1997-07-24 1999-02-16 Valentis, Inc. Ghrh expression system and methods of use
WO1999005161A1 (en) 1997-07-25 1999-02-04 Ligand Pharmaceuticals Incorporated HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
ES2320603T3 (es) 1997-07-30 2009-05-25 Emory University Sistemas de expresion, vectores, adn, proteinas de mineralizacion osea novedosos.
DE69829857T2 (de) 1997-08-21 2006-02-02 Quark Biotech, Inc., Pleasanton Hypoxie-regulierte gene
US20030104973A1 (en) * 1997-08-21 2003-06-05 Quark Biotech, Inc. Hypoxia-regulated genes
US7973156B2 (en) * 1997-08-21 2011-07-05 Quark Pharmaceuticals Inc. Hypoxia-regulated genes
EP1892299A3 (en) * 1997-09-19 2011-07-20 Life Technologies Corporation Sense mRNA therapy
US20030083272A1 (en) * 1997-09-19 2003-05-01 Lahive & Cockfield, Llp Sense mrna therapy
WO1999018116A1 (en) * 1997-10-07 1999-04-15 Smithkline Beecham Corporation Method for modulating gene expression
US7687057B2 (en) 1998-01-09 2010-03-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem In vitro micro-organs, and uses related thereto
EP2009109A1 (en) 1998-01-12 2008-12-31 Pedro Jose G protein-related kinase mutants in essential hypertension
CA2318403A1 (en) 1998-01-21 1999-07-29 Sugen, Inc. Human orthologues of wart
CA2369172A1 (en) 1998-04-14 1999-10-21 Sugen, Inc. Ste20-related protein kinases
US6395253B2 (en) 1998-04-23 2002-05-28 The Regents Of The University Of Michigan Microspheres containing condensed polyanionic bioactive agents and methods for their production
WO2000009086A2 (en) 1998-08-14 2000-02-24 Valentis, Inc. Protected one-vial formulation for nucleic acid molecules, methods of making the same by in-line mixing, and related products and methods
EP1115857A1 (fr) * 1998-09-25 2001-07-18 Aventis Pharma S.A. Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire
FR2783839B1 (fr) * 1998-09-25 2002-12-06 Aventis Pharma Sa Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire
WO2000023606A1 (en) 1998-10-22 2000-04-27 Medical College Of Georgia Institute, Inc. Long terminal repeat, enhancer, and insulator sequences for use in recombinant vectors
US6861442B1 (en) 1998-12-30 2005-03-01 Sugen, Inc. PYK2 and inflammation
DE19907099A1 (de) * 1999-02-19 2000-09-07 Theragene Biomedical Lab Gmbh Hormon-Hormonrezeptorkomplexe und Nukleinsäurekonstrukte und ihre Verwendung in der Gentherapie
US6759393B1 (en) * 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
US20030131364A1 (en) * 1999-04-27 2003-07-10 Karen Duff Method for producing transgenic animal models with modulated phenotype and animals produced therefrom
US6787318B1 (en) * 1999-06-01 2004-09-07 Roskamp Research Institute, Llc Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US20070160615A1 (en) * 1999-06-01 2007-07-12 Jun Tan Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of Alzheimer's disease
US20060127366A1 (en) * 1999-06-25 2006-06-15 Mitrani Eduardo N Method and device for inducing biological processes by micro-organs
JP2003535025A (ja) * 1999-06-25 2003-11-25 イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム 微小器官で血管新生を誘発する方法
US6770740B1 (en) 1999-07-13 2004-08-03 The Regents Of The University Of Michigan Crosslinked DNA condensate compositions and gene delivery methods
US20040192593A1 (en) * 1999-07-26 2004-09-30 Baylor College Of Medicine Protease resistant ti-growth hormone releasing hormone
AU772752B2 (en) 1999-07-26 2004-05-06 Baylor College Of Medicine Super-active porcine growth hormone releasing hormone analog
US6875582B1 (en) 1999-08-19 2005-04-05 Omniscience Pharmaceuticals, Inc. Methods and targets of antibiotic resistance
US6486134B2 (en) * 1999-09-17 2002-11-26 Leadergene Limited Gene treatment to enhance feed efficiency and growth rate of livestock
US6998232B1 (en) 1999-09-27 2006-02-14 Quark Biotech, Inc. Methods of diagnosing bladder cancer
CN1182874C (zh) * 1999-10-29 2005-01-05 安增子摩祺株式会社 糖尿病性局部缺血疾病的基因治疗制剂
AU2001225441A1 (en) * 2000-01-24 2001-07-31 Agricultural Research Organization The Volcani Center Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
GB0011278D0 (en) 2000-05-10 2000-06-28 Univ London Repair of nerve damage
US6596526B1 (en) 2000-06-09 2003-07-22 Baxter Aktiengesellschaft Furin polypeptides with improved characteristics
HUP0300810A2 (hu) 2000-07-20 2003-08-28 M.G.V.S. Ltd. Mesterséges értranszplantátum, valamint ennek létrehozása és alkalmazása
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
WO2002018954A2 (en) 2000-08-30 2002-03-07 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
AU2001296354A1 (en) 2000-09-25 2002-04-02 Baylor College Of Medicine Improved system for regulation of transgene expression
CA2437201C (en) 2001-02-02 2008-11-18 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
EP1377156A4 (en) * 2001-03-22 2007-08-29 Scentgene Pollination Ltd METHOD FOR INCREASING ENTOMOPHILIA
WO2002097099A1 (en) * 2001-05-29 2002-12-05 Valentis, Inc. Regulated expression of ghrh
AU2002324909A1 (en) * 2001-09-07 2003-03-24 Baylor College Of Medicine Linear dna fragments for gene expression
AR037038A1 (es) * 2001-10-26 2004-10-20 Baylor College Medicine Una composicion y metodo para alterar la masa corporal magra y las propiedades oseas en un sujeto
WO2003048298A2 (en) * 2001-12-05 2003-06-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nanoparticles containing polymeric nucleic acid homologs, pharmaceutical compositions and articles of manufacture containing same and methods of use thereof
AU2002357143B2 (en) 2001-12-11 2009-07-30 Advisys, Inc. Growth hormone releasing hormone supplementation for treating chronically ill subjects
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
ATE556714T1 (de) 2002-02-01 2012-05-15 Life Technologies Corp Doppelsträngige oligonukleotide
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
US7250405B2 (en) * 2002-02-07 2007-07-31 Baylor College Of Medicine Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1359160A1 (en) * 2002-02-28 2003-11-05 Pfizer Products Inc. Androgen receptor overexpressing skeletal myoblasts
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
AU2003249208B2 (en) * 2002-07-16 2010-03-04 Vgx Pharmaceuticals, Llc Codon optimized synthetic plasmids
US20040146949A1 (en) * 2002-10-25 2004-07-29 Jun Tan Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease
US20060206950A1 (en) * 2002-11-04 2006-09-14 Kaelin William G Jr In vivo imaging of e2f-fegulated bioluminescent proteins
MXPA05004860A (es) * 2002-11-04 2005-08-18 Advisys Inc Promotores musculares sinteticos con actividades que exceden las secuencias reguladoras de origen natural en las celulas cardiacas.
AU2003298675A1 (en) * 2002-11-22 2004-06-18 You-Jun Fei NaCT AS A TARGET FOR LIFESPAN EXPANSION AND WEIGHT REDUCTION
CA2513743C (en) * 2003-01-28 2013-06-25 Advisys, Inc. Reducing culling in herd animals growth hormone releasing hormone (ghrh)
CA2557737C (en) 2003-03-12 2014-08-05 Advisys, Inc. Insulin-like growth factor (igf-i) plasmid-mediated supplementation for therapeutic applications
TW200424214A (en) * 2003-04-21 2004-11-16 Advisys Inc Plasmid mediated GHRH supplementation for renal failures
CA2575926C (en) * 2003-08-04 2014-02-25 Advisys, Inc. Canine specific growth hormone releasing hormone
WO2005059100A2 (en) * 2003-12-12 2005-06-30 New York University Methods and compositions relating to cystatin c
ATE467417T1 (de) * 2003-12-31 2010-05-15 VGX Pharmaceuticals LLC Reduzierung von arthritis und lahmheit bei personen unter supllement von wachstumshormon freisetzendem hormon (ghrh)
WO2005073371A2 (en) * 2004-01-20 2005-08-11 Advisys, Inc. Enhanced secretion/retention of growth hormone releasing hormone (ghrh) from muscle cells by species-specific signal peptide
US20090005333A1 (en) * 2004-01-26 2009-01-01 Vgx Pharmaceuticlas, Inc. Reducing culling in herd animals growth hormone releasing hormone (ghrh)
US20060019241A1 (en) * 2004-04-20 2006-01-26 Vadivel Ganapathy Na+ and CI-coupled transport system for endogenous opioid peptides
US7544855B2 (en) 2004-04-23 2009-06-09 Buck Institute Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
US20060025368A1 (en) * 2004-07-23 2006-02-02 Advisys, Inc. Growth hormone releasing hormone enhances vaccination response
US7846720B2 (en) * 2005-01-26 2010-12-07 Vgx Pharmaceuticals, Inc. Optimized high yield synthetic plasmids
NZ538097A (en) * 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
WO2007088418A1 (en) 2006-01-31 2007-08-09 Multi Gene Vascular Systems, Inc. Drug-eluting intravascular prostheses and methods of use
WO2007103683A2 (en) * 2006-03-01 2007-09-13 Roskamp Research Llc Compounds for inhibiting beta-amyloid production
WO2008006019A2 (en) * 2006-07-06 2008-01-10 Advisys Inc. Growth hormone releasing hormone treatment to decrease cholesterol levels
WO2008013918A2 (en) * 2006-07-26 2008-01-31 Myelin Repair Foundation, Inc. Cell cycle regulation and differentiation
US8124598B2 (en) 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
CN102886052B (zh) 2006-09-14 2014-07-30 迈德詹尼克斯医疗以色列有限公司 长效药物制剂
EP2120557A4 (en) * 2006-12-08 2010-02-10 Roskamp Res Llc POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION
WO2008152507A2 (en) 2007-03-16 2008-12-18 Multigene Vascular Systems, Inc. Compositions and methods for treating ophthalmic disorders
EP2144935A2 (en) 2007-03-29 2010-01-20 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
US8811535B2 (en) * 2009-07-17 2014-08-19 Mitre Corporation Time-frequency space constructions of families of signals
US20110070199A1 (en) * 2009-09-21 2011-03-24 Scheiber Ii Lane Bernard Adaptable modified virus vector to deliver ribosomal ribonucleic acid combined with messenger ribonucleic acid as a medical treatment device to manage diabetes mellitus and other protein deficient dieases
CA2802726A1 (en) 2010-06-15 2011-12-22 Medgenics Medical Israel Ltd. Long lasting drug formulations
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
US8993316B2 (en) 2011-11-16 2015-03-31 Brian P. Hanley Methods and compositions for gene therapy and GHRH therapy
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP3060144A1 (en) 2013-10-24 2016-08-31 Medgenics Medical Israel, Ltd Micro-organs providing sustained delivery of a therapeutic polypeptide and methods of use thereof
ES2782380T5 (es) 2013-10-30 2023-05-08 Univ Missouri Método de especificación y cultivo de linaje del músculo esquelético escalable
CA3036831A1 (en) 2016-09-14 2018-03-22 Modernatx, Inc. High purity rna compositions and methods for preparation thereof
WO2018208628A1 (en) 2017-05-06 2018-11-15 Memphis Meats, Inc. Compositions and methods for increasing the culture density of a cellular biomass within a cultivation infrastructure
WO2019014652A1 (en) 2017-07-13 2019-01-17 Memphis Meats, Inc. COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF CELL CULTURES USED IN FOOD PRODUCTION
CN113874502A (zh) 2019-03-11 2021-12-31 摩登纳特斯有限公司 补料分批体外转录方法
EP4274607A1 (en) 2021-01-11 2023-11-15 ModernaTX, Inc. Seasonal rna influenza virus vaccines
DE102021122096A1 (de) * 2021-08-26 2023-03-02 Forschungsinstitut für Nutztierbiologie IGF-1, IGFBP-2 und Insulin umfassende Zusammensetzungen und ihre Verwendung
WO2023240152A1 (en) 2022-06-07 2023-12-14 Upside Foods, Inc. Engineering cell lines capable of proliferation in growth factor free media formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1353839A (fr) * 1963-04-10 1964-02-28 Tube en résine avec armature incorporée
US4783405A (en) * 1983-01-18 1988-11-08 Eli Lilly And Company Recombinant DNA expression vectors useful in bacillus and other host cells
EP0174608A1 (en) * 1984-09-13 1986-03-19 The Board Of Trustees Of The Leland Stanford Junior University Beta-actin gene and regulatory elements, preparation and use
GB8529014D0 (en) * 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
MX170815B (es) * 1986-07-14 1993-09-20 Gates Rubber Co Un aditamiento de niple mejorado capaz de incrustarse en el termino de un articulo de manguera elastomerica, metodo para fabricarlo y el articulo para su aplicacion
EP0832981A1 (en) * 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
JPH0791320B2 (ja) * 1988-03-17 1995-10-04 ヤマサ醤油株式会社 組換えヒト心筋ミオシン
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5538722A (en) * 1989-06-13 1996-07-23 Stanford University Isolation, growth, differentiation and genetic engineering of human muscle cells
WO1991011522A1 (en) * 1990-01-26 1991-08-08 Baylor College Of Medicine MUTATED PROMOTER REGION FROM CHICKEN SKELETAL α-ACTIN GENE
WO1991012329A2 (en) * 1990-02-12 1991-08-22 Board Of Regents, The University Of Texas System Satellite cell proliferation in adult skeletal muscle
FI914947A0 (fi) * 1990-02-22 1991-10-21 Biogen Inc Foerbaettrad expression av polypeptider.
GB9305091D0 (en) * 1993-03-12 1993-04-28 Thrombosis Res Inst Eukaryotic expression vectors driven by a novel strong mammalian cell promoter

Also Published As

Publication number Publication date
AU3124693A (en) 1993-06-07
US5756264A (en) 1998-05-26
EP0635060A4 (en) 1995-04-19
WO1993009236A1 (en) 1993-05-13
CA2122617A1 (en) 1993-05-13
PT101042B (pt) 1999-11-30
EP0635060A1 (en) 1995-01-25
US5298422A (en) 1994-03-29
JPH07500967A (ja) 1995-02-02
AU660751B2 (en) 1995-07-06

Similar Documents

Publication Publication Date Title
PT101042A (pt) Sistema de vectores de expressao miogenicos
BR9205838A (pt) Sistema de conteinerização
ITMI912542A0 (it) Sistema di cablaggio
FI924194L (fi) Naolelektrodsystem
FI935337L (fi) Feldetektionssystem
DE69318447D1 (de) Erkennungssystem
BR9205088A (pt) Sistema de terraplanagem
FI930047L (fi) System foer ekoavlaegsning omfattande en ekobildsavlaegsningsreferenssignal
BR9203190A (pt) Sistema de desengate
BR9103099A (pt) Sistema de xampu
BR9104729A (pt) Sistema de alarme salva-vidas
BR9105339A (pt) Sistema de radar
MX9205300A (es) Sistema de plastisol
BR9401762A (pt) Sistema de telealarme
BR9106089A (pt) Sistema de conducao de mercadorias
DE69227236D1 (de) Behältersysteme
BR9203955A (pt) Sistema transportador
BR9202308A (pt) Sistema de conteinerizacao
ATA104791A (de) Rohrleitungssystem
FI920865A7 (fi) Regeneringssystem foer tygsaeckfilter
BR7100553U (pt) Sistema de encaixe conico
ITTO910321V0 (it) Sistema di imballaggio
ITPV920016A0 (it) Sistema easytaxi
BR7101395U (pt) Sistema de lacre aplicacao em embalagem
BR9205335A (pt) Sistema de regulatem antibioqueio

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19930709

FG3A Patent granted, date of granting

Effective date: 19990830

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20010228